In the era of DOACs, risk for CTEPH following pulmonary embolism is affected by multiple factors, including gender and heart load.

The Chronic Thromboembolic Pulmonary Hypertension (CTEPH) program at Baylor St. Luke’s Medical Center is one of a handful of specialized programs in the country offering expert multidisciplinary care ...

Treprostinil is under clinical development by United Therapeutics and currently in Phase III for Idiopathic Pulmonary Fibrosis.

Mosliciguat is under clinical development by Bayer and currently in Phase I for Kidney Disease (Nephropathy). According to GlobalData, Phase I drugs for Kidney Disease (Nephropathy) have a 71% phase ...

The top articles about pulmonary arterial hypertension (PAH) in 2024 included FDA approvals, the effect of salt substitutes ...

may lead to pulmonary hypertension, a lethal complication of chronic pulmonary thromboembolism. There are few viable treatment options for pulmonary hypertension, but pulmonary ...

The following is a summary of “Relevance of patient-centered actigraphy measures in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a qualitative interview study,” ...

Direct treatment options exist for only two types: pulmonary artery hypertension (PAH) and chronic thromboembolic pulmonary ...

A high index of suspicion combined with a meticulous history and physical examination is paramount in the evaluation of patients with pulmonary hypertension. Careful attention should be given to ...

Pulmonary hypertension (PH) is a condition that occurs when your blood pressure in the blood vessels between the heart and ...